A Randomized Multicenter Study of Ibrutinib in Combination With Pomalidomide and Dexamethasone in Subjects With Relapsed/Refractory Multiple Myeloma
Active, no longer recruiting
Phase of Trial: Phase I/II
Latest Information Update: 20 Dec 2017
At a glance
- Drugs Ibrutinib (Primary) ; Dexamethasone; Pomalidomide
- Indications Multiple myeloma
- Focus Adverse reactions; Therapeutic Use
- Sponsors Pharmacyclics
- 14 Dec 2017 Status changed from recruiting to active, no longer recruiting.
- 29 Nov 2017 This trial has been completed in Spain.
- 15 Apr 2016 Status changed from not yet recruiting to recruiting.